A New Strategy for Obesity Treatment: Revealing the Frontiers of Anti-obesity Medications.
Pan-Feng HuangQi-Yu WangRong-Bin ChenYa-Di WangYuan-Yuan WangJiang-Hua LiuXin-Hua XiaoZhe-Zhen LiaoPublished in: Current molecular medicine (2024)
Obesity dramatically increases the risk of type 2 diabetes, fatty liver, hypertension, cardiovascular disease, and cancer, causing both declines in quality of life and life expectancy, which is a serious worldwide epidemic. At present, more and more patients with obesity are choosing drug therapy. However, given the high failure rate, high cost, and long design and testing process for discovering and developing new anti-obesity drugs, drug repurposing could be an innovative method and opportunity to broaden and improve pharmacological tools in this context. Because different diseases share molecular pathways and targets in the cells, anti-obesity drugs discovered in other fields are a viable option for treating obesity. Recently, some drugs initially developed for other diseases, such as treating diabetes, tumors, depression, alcoholism, erectile dysfunction, and Parkinson's disease, have been found to exert potential anti-obesity effects, which provides another treatment prospect. In this review, we will discuss the potential benefits and barriers associated with these drugs being used as obesity medications by focusing on their mechanisms of action when treating obesity. This could be a viable strategy for treating obesity as a significant advance in human health.
Keyphrases
- insulin resistance
- metabolic syndrome
- weight loss
- type diabetes
- high fat diet induced
- weight gain
- cardiovascular disease
- human health
- risk assessment
- adipose tissue
- squamous cell carcinoma
- emergency department
- coronary artery disease
- oxidative stress
- glycemic control
- stem cells
- signaling pathway
- cell proliferation
- induced apoptosis
- physical activity
- climate change
- cell therapy
- cardiovascular risk factors
- papillary thyroid
- pi k akt